Pill Identifier App

Generic Pataday Availability

Pataday is a brand name of olopatadine ophthalmic, approved by the FDA in the following formulation(s):

PATADAY (olopatadine hydrochloride - solution/drops; ophthalmic)

  • Manufacturer: ALCON PHARMS LTD
    Approval date: December 22, 2004
    Strength(s): EQ 0.2% BASE [RLD]

Has a generic version of Pataday been approved?

No. There is currently no therapeutically equivalent version of Pataday available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pataday. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Topical ophthalmic formulations for treating allergic eye diseases
    Patent 5,641,805
    Issued: June 24, 1997
    Inventor(s): Hayakawa; Eiji & Nakakura; Masashi & Robertson; Stella M. & Yanni; John Michael
    Assignee(s): Alcon Laboratories, Inc. Kyowa Hakko Kogyo Co. Ltd.
    Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
    Patent expiration dates:
    • June 6, 2015
      ✓ 
      Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
    • December 6, 2015
      ✓ 
      Pediatric exclusivity
  • Olopatadine formulations for topical administration
    Patent 6,995,186
    Issued: February 7, 2006
    Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
    Assignee(s): Alcon, Inc.
    Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Patent expiration dates:
    • November 12, 2023
      ✓ 
      Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
      ✓ 
      Drug product
    • May 12, 2024
      ✓ 
      Pediatric exclusivity
  • Olopatadine formulations for topical administration
    Patent 7,402,609
    Issued: July 22, 2008
    Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
    Assignee(s): Alcon, Inc.
    Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Patent expiration dates:
    • June 19, 2022
      ✓ 
      Drug product
    • December 19, 2022
      ✓ 
      Pediatric exclusivity

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web4)